Osiris Therapeutics (OSIR) 12.39 $OSIR
Osiris receives USD15m cash payment for Prochymal business acquisition
M2 - Thu Apr 10, 7:06AM CDT
US-based stem cell company Osiris Therapeutics (NasdaqGM :OSIR) reported on Wednesday the receipt of the next payment of USD15m in cash from Mesoblast under the Purchase Agreement relating to the Prochymal business.
Osiris Announces Receipt of $15 Million Cash Payment for Prochymal
Business Wire - Wed Apr 09, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.
3 Big-Volume Stocks in Breakout Territory
at The Street - Mon Apr 07, 8:24AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Prochymal (remestemcel-L) Crohn's Disease Report - Forecast and Market Analysis to 2022
M2 - Mon Apr 07, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bkqdzc/prochymal) has announced the addition of the "Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022" report to their offering. The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period. Osiris Therapeutics is developing Prochymal (remestemcel-L) for the treatment of moderate to severe CD. Prochymal is a preparation of mesenchymal stem cells (MSCs) obtained from the bone marrow of healthy donors between the ages of 18 and 30 years, which are cultured and formulated for IV infusion. MSCs have the capacity to form a variety of highly specialized cell types, including bone, cartilage, muscle, tendon, fat, and liver cells, and they also display the ability to assist in tissue repair. Osiris Therapeutics' novel cell-based therapeutic approach aims to address localized inflammation in CD without targeting specific systemic components of the innate and adaptive immune systems, the former being the case with all the existing therapies. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Prochymal (remestemcel-L) 9 Appendix For more information visit http://www.researchandmarkets.com/research/bkqdzc/prochymal
Osiris Therapeutics elects Theresa K Dixon as GM of Market Access and Reimbursement
M2 - Thu Mar 27, 5:50AM CDT
Stem cell company Osiris Therapeutics (NasdaqGM:OSIR) reported on Wednesday the addition of Theresa K Dixon as general manager of its Market Access and Reimbursement.
Osiris Therapeutics Announces Theresa K. Dixon as General Manager of Market Access and Reimbursement
Business Wire - Wed Mar 26, 7:02AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, is pleased to announce the appointment of Theresa K. Dixon, to General Manager, Market Access and Reimbursement, reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer.
Osiris Therapeutics to Present at the 2nd Annual Regen Med Investor Day
Business Wire - Mon Mar 24, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2nd Annual Regen Med Investor Day on Wednesday, March 26, 2014 at 4:15 p.m. ET in New York City.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Osiris Therapeutics Reports Change in Tax Benefit Allocation for Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Mar 11, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today an accounting adjustment to its Fourth Quarter and Full Year 2013 financial results reported on March 5. The adjustment results from a change in the allocation of income tax benefits from continuing operations to discontinued operations. There is no change in net income, cash or cash flow.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Osiris Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference
Business Wire - Mon Mar 10, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2014 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 2:20 p.m. ET (1:20 a.m. CT) in New Orleans.
2014 Mesenchymal Stem Cells Global Strategic Business Report - Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
M2 - Mon Mar 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hz38cb/mesenchymal_stem) has announced the addition of the "Mesenchymal Stem Cells - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Mesenchymal Stem Cells (MSCs) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET DRIVERS, TRENDS & ISSUES - Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies - Adult Stem Cells Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research - Adult Stem Cells and Embryonic Stem Cells - A Comparison - MSCs versus Embryonic or Induced Pluripotent Stem Cells - MSC Therapies Immune to Ethical Issues Applicable to Embryonic Stem Cells - MSCs - A Potential Vehicle for 'Targeted Drug Delivery' - Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements - Major Challenges Confronting Mesenchymal Stem Cell Market 3. STEM CELL MARKET - A MACRO PERSPECTIVE 4. REVIEW OF SELECT MAJOR STEM CELL VARIANTS - Adult Stem Cells - A Low Risk Investment - Adult Stem Cells Garner More Investments for Research - Low Versatility - A Major Limiting Factor of Adult Stem Cells - Hematopoietic Stem Cells - Enjoying Enduring Success - Restraining Factors - Induced Pluripotent Stem Cells - An Alternative to ESCs - A Peek into the Discovery of iPS - Drug Development - A Major Application for iPS - Use of iPS for Regenerative Medicine - Establishing iPS Cell Banks - Intractable and Congenital Disease Treatments - Embryonic Stem Cells to Transfigure Medicine - Ethical Issues and Technical Hurdles Bog Down hESC Research - Lack of Safety and Efficacy Data - A Key Concern 5. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION 6. PRODUCT OVERVIEW 7. PRODUCT INNOVATIONS/LAUNCHES 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Profiled The report profiles 51 companies including many key and niche players such as: - Aastrom Biosciences - Cell Applications - Celprogen - Cyagen Biosciences - EMD Millipore - Genlantis - Life Technologies - Lonza Group - Mesoblast - Neuromics - Osiris Therapeutics - Orthofix International - PromoCell - R&D Systems - ScienCell Research Laboratories - Stemcell Technologies - Stemedica Cell Technologies - StemGenesis - Trevigen - Vitro Biopharma For more information visit http://www.researchandmarkets.com/research/hz...hymal_stem About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Osiris Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:10AM CST
Osiris is focusing on its Biosurgery products which have been gaining traction over the past few quarters.
Osiris Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results: For the Full Year, Revenue Increased 3-Fold, Company was Profitable and Ended with Assets of $92.0 Million
Business Wire - Wed Mar 05, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR) the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced today its results for the fourth quarter and full year ended December 31, 2013.
Cartiform(R) Featured in Presentation at the 2014 American Academy of Orthopaedic Surgeons Annual Meeting
Business Wire - Mon Mar 03, 3:00PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that a scientific study evaluating the key attributes of Cartiform(R) will be presented at the 2014 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 11-15, in New Orleans, Louisiana. C. Thomas Vangsness, Jr., MD, Professor of Orthopedic Surgery at USC's Keck School of Medicine and Chief of Sports Medicine at University Hospital will present the findings of the study.
Osiris Therapeutics Inc elects Frank Czworka as VP & GM of Wound Care
M2 - Thu Feb 13, 5:17AM CST
Stem cell company Osiris Therapeutics Inc (NasdaqGM:OSIR) reveealed on Wednesday that Frank D Czworka Jr has been named as vice president and general manager of its Wound Care.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care
Business Wire - Wed Feb 12, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets is pleased to announce the promotion of Frank D. Czworka, Jr., to Vice President and General Manager of Wound Care. Additionally, the board voted unanimously for his appointment as a corporate officer of Osiris. Mr. Czworka joined Osiris in August 2011 and has been leading all aspects of Grafix(R) commercial and clinical development.
Osiris Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results Conference Call
Business Wire - Mon Feb 10, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it will report its financial results for fourth quarter and full year ended December 31, 2013, on Wednesday, March 5, 2014. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Wednesday, March 5, 2014, at 9:00 a.m. ET.
Commit To Buy Osiris Therapeutics At $12, Earn 16.9% Annualized Using Options
StockOptionsChannel.com - Tue Jan 21, 10:36AM CST
Investors eyeing a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $17.03/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
Osiris receives USD15m cash payment for Prochymal business acquisition
M2 - Thu Apr 10, 7:06AM CDT
US-based stem cell company Osiris Therapeutics (NasdaqGM :OSIR) reported on Wednesday the receipt of the next payment of USD15m in cash from Mesoblast under the Purchase Agreement relating to the Prochymal business.
Osiris Announces Receipt of $15 Million Cash Payment for Prochymal
Business Wire - Wed Apr 09, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.
3 Big-Volume Stocks in Breakout Territory
at The Street - Mon Apr 07, 8:24AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Prochymal (remestemcel-L) Crohn's Disease Report - Forecast and Market Analysis to 2022
M2 - Mon Apr 07, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bkqdzc/prochymal) has announced the addition of the "Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022" report to their offering. The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period. Osiris Therapeutics is developing Prochymal (remestemcel-L) for the treatment of moderate to severe CD. Prochymal is a preparation of mesenchymal stem cells (MSCs) obtained from the bone marrow of healthy donors between the ages of 18 and 30 years, which are cultured and formulated for IV infusion. MSCs have the capacity to form a variety of highly specialized cell types, including bone, cartilage, muscle, tendon, fat, and liver cells, and they also display the ability to assist in tissue repair. Osiris Therapeutics' novel cell-based therapeutic approach aims to address localized inflammation in CD without targeting specific systemic components of the innate and adaptive immune systems, the former being the case with all the existing therapies. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Prochymal (remestemcel-L) 9 Appendix For more information visit http://www.researchandmarkets.com/research/bkqdzc/prochymal
Osiris Therapeutics elects Theresa K Dixon as GM of Market Access and Reimbursement
M2 - Thu Mar 27, 5:50AM CDT
Stem cell company Osiris Therapeutics (NasdaqGM:OSIR) reported on Wednesday the addition of Theresa K Dixon as general manager of its Market Access and Reimbursement.
Osiris Therapeutics Announces Theresa K. Dixon as General Manager of Market Access and Reimbursement
Business Wire - Wed Mar 26, 7:02AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, is pleased to announce the appointment of Theresa K. Dixon, to General Manager, Market Access and Reimbursement, reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer.
Osiris Therapeutics to Present at the 2nd Annual Regen Med Investor Day
Business Wire - Mon Mar 24, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2nd Annual Regen Med Investor Day on Wednesday, March 26, 2014 at 4:15 p.m. ET in New York City.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Osiris Therapeutics Reports Change in Tax Benefit Allocation for Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Mar 11, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced today an accounting adjustment to its Fourth Quarter and Full Year 2013 financial results reported on March 5. The adjustment results from a change in the allocation of income tax benefits from continuing operations to discontinued operations. There is no change in net income, cash or cash flow.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Osiris Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference
Business Wire - Mon Mar 10, 7:01AM CDT
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 2014 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 11, 2014 at 2:20 p.m. ET (1:20 a.m. CT) in New Orleans.
2014 Mesenchymal Stem Cells Global Strategic Business Report - Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
M2 - Mon Mar 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hz38cb/mesenchymal_stem) has announced the addition of the "Mesenchymal Stem Cells - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Mesenchymal Stem Cells (MSCs) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. MARKET DRIVERS, TRENDS & ISSUES - Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies - Adult Stem Cells Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research - Adult Stem Cells and Embryonic Stem Cells - A Comparison - MSCs versus Embryonic or Induced Pluripotent Stem Cells - MSC Therapies Immune to Ethical Issues Applicable to Embryonic Stem Cells - MSCs - A Potential Vehicle for 'Targeted Drug Delivery' - Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements - Major Challenges Confronting Mesenchymal Stem Cell Market 3. STEM CELL MARKET - A MACRO PERSPECTIVE 4. REVIEW OF SELECT MAJOR STEM CELL VARIANTS - Adult Stem Cells - A Low Risk Investment - Adult Stem Cells Garner More Investments for Research - Low Versatility - A Major Limiting Factor of Adult Stem Cells - Hematopoietic Stem Cells - Enjoying Enduring Success - Restraining Factors - Induced Pluripotent Stem Cells - An Alternative to ESCs - A Peek into the Discovery of iPS - Drug Development - A Major Application for iPS - Use of iPS for Regenerative Medicine - Establishing iPS Cell Banks - Intractable and Congenital Disease Treatments - Embryonic Stem Cells to Transfigure Medicine - Ethical Issues and Technical Hurdles Bog Down hESC Research - Lack of Safety and Efficacy Data - A Key Concern 5. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION 6. PRODUCT OVERVIEW 7. PRODUCT INNOVATIONS/LAUNCHES 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Profiled The report profiles 51 companies including many key and niche players such as: - Aastrom Biosciences - Cell Applications - Celprogen - Cyagen Biosciences - EMD Millipore - Genlantis - Life Technologies - Lonza Group - Mesoblast - Neuromics - Osiris Therapeutics - Orthofix International - PromoCell - R&D Systems - ScienCell Research Laboratories - Stemcell Technologies - Stemedica Cell Technologies - StemGenesis - Trevigen - Vitro Biopharma For more information visit http://www.researchandmarkets.com/research/hz...hymal_stem About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Osiris Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:10AM CST
Osiris is focusing on its Biosurgery products which have been gaining traction over the past few quarters.
Osiris Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results: For the Full Year, Revenue Increased 3-Fold, Company was Profitable and Ended with Assets of $92.0 Million
Business Wire - Wed Mar 05, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR) the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced today its results for the fourth quarter and full year ended December 31, 2013.
Cartiform(R) Featured in Presentation at the 2014 American Academy of Orthopaedic Surgeons Annual Meeting
Business Wire - Mon Mar 03, 3:00PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that a scientific study evaluating the key attributes of Cartiform(R) will be presented at the 2014 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 11-15, in New Orleans, Louisiana. C. Thomas Vangsness, Jr., MD, Professor of Orthopedic Surgery at USC's Keck School of Medicine and Chief of Sports Medicine at University Hospital will present the findings of the study.
Osiris Therapeutics Inc elects Frank Czworka as VP & GM of Wound Care
M2 - Thu Feb 13, 5:17AM CST
Stem cell company Osiris Therapeutics Inc (NasdaqGM:OSIR) reveealed on Wednesday that Frank D Czworka Jr has been named as vice president and general manager of its Wound Care.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care
Business Wire - Wed Feb 12, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets is pleased to announce the promotion of Frank D. Czworka, Jr., to Vice President and General Manager of Wound Care. Additionally, the board voted unanimously for his appointment as a corporate officer of Osiris. Mr. Czworka joined Osiris in August 2011 and has been leading all aspects of Grafix(R) commercial and clinical development.
Osiris Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results Conference Call
Business Wire - Mon Feb 10, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it will report its financial results for fourth quarter and full year ended December 31, 2013, on Wednesday, March 5, 2014. Lode Debrabandere, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Wednesday, March 5, 2014, at 9:00 a.m. ET.
Commit To Buy Osiris Therapeutics At $12, Earn 16.9% Annualized Using Options
StockOptionsChannel.com - Tue Jan 21, 10:36AM CST
Investors eyeing a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $17.03/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
